Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus osimertinib versus osimertinib in EGFR T790M-positive advanced non-squamous NSCLC after first- or second-generation EGFR-TKI resistance
ChiCTR1900024318Phase 4Recruiting
- Sponsor
- Shulan Health
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of osimertinib and anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shulan Health. Primary endpoints: progression-free survival, objective response rate and 3 more. Started Jun 2019; status: recruiting.
02
Drugs
osimertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900024318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024318.